Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Executive Summary

Neurocrine submits NDA for its VMAT inhibitor valbenazine for tardive dyskinesia, getting to FDA ahead of Teva, which is developing a similar product, deutetrabenazine, for the same indication.

Advertisement

Related Content

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD
Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016
Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
Teva CRL Response For Huntington’s Drug Targeted For September
Teva's Huntington's Rejection May Be Neurocrine's Good Fortune
Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel